Uniphar Secures 10th Cell and Gene Therapy Project
April 17, 2025 | Branding, Creative and Design, Digital Communications, Equitable access, Health policy and government affairs, Market Access, Medical Communications, Patient support and adherence, Sales, cell and gene therapy, clinical research, medical education, pharmacy, regulatory affairs
[Dublin, April 17th 2025] Uniphar, a global leader in pharmaceutical and medtech solutions has announced the launch of its 10th cell and gene therapy (CGT) project. The milestone reinforces Uniphar’s commitment to ensuring life-changing therapies reach patients worldwide, and builds on Uniphar’s established CGT expertise in therapeutic areas such as neuromuscular diseases and oncology, with a significant number of projects addressing paediatric populations.
To date, Uniphar has developed go-to-market and clinical development strategies and facilitated access to innovative cell and gene treatments in over 50 countries, benefiting more than 600 patients.
With a strong presence in Europe and expansion into the U.S., Uniphar has made it possible to enable cell and gene entry into underserved regions, working closely with regulatory authorities, healthcare providers and logistics partners to streamline treatment delivery. However, equitable access to these therapies remains a significant hurdle.
“The promise of cell and gene therapies continues to grow, as does the expectations of the patient communities who may benefit. Bringing these complex therapies into new markets presents a unique set of challenges, from regulatory hurdles to complex supply chain logistics,” said Tom Smith, Strategic Director of Cell and Gene Therapies at Uniphar. “By continuously refining our approach and building tailored and scalable infrastructure, we can ensure these breakthrough therapies reach patients worldwide as quickly and efficiently as possible, particularly in areas with a high unmet need.”
Partnering with over 200 organizations worldwide, Uniphar provides support throughout the pharmaceutical development lifecycle—from early-stage medical strategy to patient access solutions. Leveraging its extensive expertise in pharmaceutical access and distribution, Uniphar’s expanded access programmes (EAPs) have enabled pharmaceutical companies to navigate the complexities of early patient access, allowing therapies like cell and gene to reach patients before full commercial availability. Through these initiatives, Uniphar has generated approximately half a billion dollars in revenue for cell and gene pharmaceutical partners, reinforcing the sustainability of early access models. These programs also provide valuable insights for regulatory discussions, pricing negotiations, and commercial launch strategies.
As Uniphar looks ahead to 2025 and beyond, the company remains focused on enhancing its CGT platforms aligned to its wider business offering as a global leader in pharmaceutical and medtech solutions, expanding its strategic partnerships, and further refining its access solutions. With new EAPs set to launch, Uniphar continues to drive innovation in early access models, ensuring that more patients can benefit from breakthrough treatments.
The news comes after Uniphar announced its full year results for the year ending 31 December 2024, with pharma and medtech divisions delivering organic growth of 17.6% and 9.1% respectively, while supply chain and retail saw a 5.5% increase in gross profit.
For more information on Uniphar, visit https://uniphar.com/cellandgene/
ENDS
Media relations:
Heather Hopkin at TALA at heather.hopkin@teamtala.com / +44 (0)7545536147
Beth O’Shea at TALA at beth.oshea@teamtala.com / +44 (0)7891481003
Notes to editors
CGT global outlook:
Research shows that spending on CGT has risen rapidly, reaching $5.9 billion globally in 2023—a 38% increase from 2022i. The global CGT market was estimated at $21.28 billion in 2024 and is predicted to grow to around $117.46 billion by 2034. In the U.S., the market exceeded $10.59 billion in 2024.ii
About Uniphar
Uniphar Group is a trusted global partner to pharma, medtech and biotech companies, working to improve patient access to medicines around the world. Uniphar’s team of experts harness the capabilities, infrastructure and expertise of a diversified pharmaceutical service provider with 57 years’ building success stories with 200+ multinational clients.
Our understanding of the shifting market dynamics allows us to deliver tailored specialist services and solutions for our clients’ changing needs. Uniphar Pharma comprises Uniphar | Access, Uniphar | Medical, and Uniphar | Commercial – together our combined capabilities make us your trusted partner to unlock access for your patients to innovative therapies and optimize value for brands globally. Working from clinical development to commercialization, our end-to-end services remove barriers to launch, increase access and optimize brands.
This content was provided by Uniphar
Company Details
Latest Content from Uniphar
Governor Josh Stein marks strengthening North Carolina-Ireland trade relationship at Uniphar facility visit
The event speaker panel, from left to right: Brian Kiefel, Ireland Site Leader & CTO, Honeywell; Christopher Chung, Chief Executive Officer, EDPNC; Tom Scrivener, Group COO, Bank of America; Ambassador…
J‑Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment
Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial TOKYO, Japan and DUBLIN, Ireland — [June 16, 2026] J‑Pharma Co., Ltd., a clinical-stage biotechnology…
Durbin PLC becomes Uniphar, bolstering medicine access amidst growing healthcare demands
Against the backdrop of widespread medicine shortages, Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, expanding its sourcing…
Strategies to enhance the provider and patient EAP experience
Expanded access programs (EAPs) play a multifaceted role in the drug development life cycle, serving as a critical bridge between clinical trials and commercial availability.
Uniphar | Clinical merges with BMclinical to strengthen global clinical trial services
Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and biotech companies worldwide. As part of Uniphar’s global platform supporting…
Uniphar announces U.S. expansion, integrating leading companies and appointing new senior leadership
– New integration aligns U.S. operations, unifying RRD BioPharma Development, Uniphar Clinical, Diligent Health Solutions and BESTMSLs under the Uniphar brand. – Mike Ebhardt is appointed President of Uniphar Pharma…
Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030
[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and…
Streamlining European expansion for cell and gene therapies
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe…
Current CGT landscape and future outlook
What makes CGT unique Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer…
Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals
This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of…
- 1
- 2